Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | PTAFR | P25105 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3571676 | 0.87 | MAPT (0.44) | TSHRPTAFRMAPTKMT2AKDM4E | |
| SCHEMBL28819533 | 0.85 | PTAFR (0.44) | TSHRPTAFRMAPTKMT2AKDM4E | |
| SCHEMBL27747026 | 0.85 | MEN1 (0.45) | TSHRPTAFRMAPTKMT2AKDM4E | |
| SCHEMBL28819557 | 0.84 | PTAFR (0.46) | TSHRPTAFRMAPTPOLB | |
| Hydrochloric Acid SCHEMBL27747036 | 0.84 | MEN1 (0.44) | TSHRPTAFRMAPTKMT2AKDM4E | |
| SCHEMBL28077564 | 0.84 | MEN1 (0.43) | TSHRPTAFRMAPTKMT2AKDM4E | |
| SCHEMBL28819553 | 0.84 | PTAFR (0.45) | TSHRPTAFRMAPT | |
| SCHEMBL28819516 | 0.84 | PTAFR (0.47) | TSHRPTAFRMAPTKMT2AKDM4E | |
| SCHEMBL28948661 | 0.83 | PTAFR (0.42) | TSHRPTAFRMAPTKMT2AKDM4E | |
| SCHEMBL28819670 | 0.83 | HSD17B10 (0.61) | TSHRPTAFRMAPTKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645785-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | claimed |
| US-20080021027-A1 | Novel benzimidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-24 | — | — | US | claimed |
| US-10071108-B2 | Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2018-09-11 | — | — | US | disclosed |
| US-20180169115-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2018-06-21 | — | — | US | disclosed |
| US-20160220586-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-08-04 | — | — | US | disclosed |
| US-7645785-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| EP-2038259-A1 | BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME | F.HOFFMANN-LA ROCHE AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| US-20080021027-A1 | Novel benzimidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-24 | — | — | US | disclosed |
| WO-2008000643-A1 | BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180169115-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | NR1H4, FXR2, FXR1 | TSHR 2137/4885PTAFR 474/4885MAPT 3520/4885 |
| US-20160220586-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | NR1H4, NR1H3, FXR2 | TSHR 2004/4885PTAFR 487/4885MAPT 3775/4885 |
| US-20080021027-A1 | Novel benzimidazole derivatives | NR1H4, GPR119, GLP1R | TSHR 106/4885PTAFR 637/4885MAPT 4740/4885 |
| US-10071108-B2 | Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection | NR1H4, FXR2, FXR1 | TSHR 2137/4885PTAFR 474/4885MAPT 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.